Trial Profile
A PROSPECTIVE MULTI-CENTRE, POST MARKETING SURVELLANCE (PMS) STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SLVRGEN (RHEGF+ 1% SILVER SULFADIAZINE + 0.2% W/W CHLORHEXIDINE GLUCONATE) IN PATIENTS WITH SUPERFICIAL PARTIAL-THICKNESS BURNS. - SLVRGEN
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Dec 2018
Price :
$35
*
At a glance
- Drugs Chlorhexidine/recombinant epidermal growth factor/silver sulfadiazine (Primary)
- Indications Burns
- Focus Adverse reactions
- Sponsors Bharat Biotech
- 11 Mar 2014 New trial record